University of Kentucky/Markey Cancer Center
Claim this profile,
Global Leader in Cancer
Global Leader in Tumors
Conducts research for Recurrence
Conducts research for Lung Cancer
Conducts research for Leukemia
540 reported clinical trials
32 medical researchers
Summary
University of Kentucky/Markey Cancer Center is a medical facility located in undefined, undefined. This center is recognized for care of Cancer, Tumors, Recurrence, Lung Cancer, Leukemia and other specialties. University of Kentucky/Markey Cancer Center is involved with conducting 540 clinical trials across 605 conditions. There are 32 research doctors associated with this hospital, such as James T. Badgett, Susanne Arnold, MD, John Villano, MD, PhD, and Zin W. Myint.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage II
2Tumors
Global LeaderStage IV
Stage I
Stage II
Top PIs
James T. BadgettUniversity of Kentucky/Markey Cancer Center7 years of reported clinical research
Expert in Tumors
Expert in Brain Tumor
44 reported clinical trials
92 drugs studied
Susanne Arnold, MDUniversity of Kentucky/Markey Cancer Center1 year of reported clinical research
Expert in Cancer
Expert in Non-Small Cell Lung Cancer
34 reported clinical trials
70 drugs studied
John Villano, MD, PhDUniversity of Kentucky/Markey Cancer Center5 years of reported clinical research
Studies Cancer
Studies Brain Tumor
20 reported clinical trials
36 drugs studied
Zin W. MyintUniversity of Kentucky/Markey Cancer Center3 years of reported clinical research
Studies Cancer
Studies Prostate Cancer
12 reported clinical trials
26 drugs studied
Clinical Trials running at University of Kentucky/Markey Cancer Center
Breast Cancer
Cancer
Lung Cancer
Non-Small Cell Lung Cancer
Squamous Cell Carcinoma
Colorectal Cancer
Tumors
Gastric Cancer
Brain Tumor
Bladder Cancer
Omitting Radiation Therapy
for Breast Cancer
The purpose of this study is to compare the effects on low risk breast cancer receiving usual care that includes regional radiation therapy, with receiving no regional radiation therapy. Researchers want to see if not giving this type of radiation treatment works as well at preventing breast cancer from coming back.
Recruiting2 awards Phase 319 criteria
Giredestrant + Hormone Therapy
for Early-Stage Breast Cancer
This trial is testing giredestrant, a medication given after initial treatment to prevent breast cancer from returning. It focuses on patients with a specific type of early-stage breast cancer that is hormone-driven and at higher risk of recurrence. Giredestrant works by blocking the hormone estrogen from helping cancer cells grow. Giredestrant has shown promise in previous studies.
Recruiting2 awards Phase 311 criteria
Pembrolizumab
for Triple-Negative Breast Cancer
The phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help researchers determine if observation will result in the same risk of cancer coming back as pembrolizumab after surgery in triple-negative breast cancer patients who achieve pathologic complete response after preoperative chemotherapy with pembrolizumab.
Recruiting2 awards Phase 319 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at University of Kentucky/Markey Cancer Center?
University of Kentucky/Markey Cancer Center is a medical facility located in undefined, undefined. This center is recognized for care of Cancer, Tumors, Recurrence, Lung Cancer, Leukemia and other specialties. University of Kentucky/Markey Cancer Center is involved with conducting 540 clinical trials across 605 conditions. There are 32 research doctors associated with this hospital, such as James T. Badgett, Susanne Arnold, MD, John Villano, MD, PhD, and Zin W. Myint.